Compare Organon & Co. Common Stock (OGN) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs T Rowe Price Group Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while T Rowe Price Group Inc trades at $99.62 (market cap $21.63B). The key difference: T Rowe Price Group Inc is far larger — about 6× Organon & Co. Common Stock's market cap, and T Rowe Price Group Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and T Rowe Price Group Inc for 115 Days on average.
| OGN | TROW | |
|---|---|---|
Market Cap | $3.62B | $21.63B |
Volume | 2,892,999 | 2,302,405 |
Sector | Health | Financials |
52-Week High | $13.81 | $121.68 |
52-Week Low | $5.70 | $86.19 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $11.04B | $18.82B |
Dividend Yield | 0.58% | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
T. Rowe Price (TROW) trades at $99.62, down 4.2% today, with a bearish technical signal despite strong fundamentals including a 29.26% net income margin and 20.1% ROE. The stock shows attractive valuation with a P/E of 10.18 and P/B of 1.97, while recent earnings beat expectations in Q1 and Q2 2026. Assets under management reached $1.90 trillion in August 2026 despite net outflows, and the company maintains a strong dividend history with 40 years of consecutive increases.
TROW presents a value opportunity with solid profitability and dividend stability, though technical weakness and mixed analyst sentiment (21% buy, 63% hold) suggest near-term caution. The consensus price target of $110.50 implies 11% upside potential, but investors face risks from market-sensitive revenue and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
